



19 February 2016

Byotrol plc

HOLDING IN COMPANY
DIRECTOR/PDMR HOLDING

Byotrol plc ("Byotrol" or the "Company"), the specialist anti-microbial technology company, was notified on 16 February 2016 that Maunby Nominees Limited ("Maunby") is interested in 23,671,710 ordinary shares of the Company, representing 8.8 per cent of the issued share capital of the Company.

Maunby Nominees Limited controls the voting rights over 23,671,710 ordinary shares of the Company, which are held by clients of Maunby Investment Management Ltd.

Of the 23,671,710 ordinary shares, 18,627,362 ordinary shares are held by Nicholas Martel, a non-executive director of Byotrol and client of Maunby. Mr Martel has a personal beneficial interest in 2,100,000, representing 0.78 per cent of the Company's issued share capital. Mr. Martel also has a non-beneficial interest in 16,527,362 ordinary equating to 6.17 per cent of the issued share capital of Byotrol. Mr Martel's personal beneficial interest in Byotrol ordinary shares remains unchanged.

Enquiries:

Byotrol plc 01925 742 000
David Traynor – Chief Executive
Dawn Marshall – Group Marketing Controller

finnCap Ltd 020 7220 0500
(Nominated Adviser & Broker)
Geoff Nash/Carl Holmes/James Thompson - Corporate Finance
Mia Gardner - Corporate Broking

Notes to Editors:

Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of residual antimicrobial technologies, maximising insights to identify, develop, formulate and commercialise cutting-edge antimicrobial technologies delivered in direct sales and in long-term licensing partnerships with consumer and professional multi-nationals.

Our patented suite of technologies deliver powerful broad-spectrum efficacy with residual performance optimised against commonly occurring and industry-specific pathogens.

For more information, please go to www.byotrol.co.uk